Structure Therapeutics (GPCR) Guggenheim SMID Cap Biotech Conference summary

Company mission and platform

• Focused on making medicines accessible through oral small molecules using structure-based drug discovery.

• Portfolio targets metabolic diseases, especially via GPCRs, with a broad pipeline including GLP-1, amylin, GIP, glucagon, and apelin.

• Oral small molecules aim to address accessibility and adherence issues seen with injectable peptides.

Pipeline progress and clinical updates

• Aleniglipron (GLP-1) is in two phase II studies (ACCESS and ACCESS-2), with data expected at year-end; studies explore dose response up to 240 mg.

• Amylin agonist GSBR-2671 is advancing to phase I, with IND-enabling studies ongoing and first-in-human trials targeted for late year.

• LPA1 program for idiopathic pulmonary fibrosis is in phase I, with data expected later this year.

• Apelin program is in long-term tox studies, focusing on safety for future combination studies.

Differentiation and clinical strategy

• Aleniglipron is differentiated by safety margins, potential for higher dosing, and proportional exposure, with no off-target effects seen in phase IIa.

• Dose titration strategy is informed by phase IIa data, showing improved tolerability and up to 6.9% placebo-adjusted weight loss at 12 weeks.

• Emphasis on optimizing tolerability and efficacy through slow titration and higher dosing.